1
Uniform particle size for enhanced flowability
Efficient production and less downtime.
Efficient production and less downtime.
Enhanced tablet strength.
Smaller tablets. Larger batch size.
Optimal release of active ingredients.
Cleaner, safer production.
NBG MCC Pura Series: DC-95 (pre-commercial)
NBG MCC Pura Series: DC-95 (pre-commercial)
We follow GMP protocol and Pharmacopeia standards for MCC.
EU ESG reporting requirements compliant.
FSC certified from traceable and sustainably managed forests.
Energy-efficient and environmentally friendly process, validated through third-party LCA.
Relentless commitment to lower carbon footprint across all operations.
Supply chain security with production in Finland.
Let’s work together to provide you with the most suitable MCC solution for your needs.